Final Results of REMOVE Study with CATUVAB® Published

Lindis Blood Care announced the publication of final results from the pivotal REMOVE study in the Journal of Clinical Anesthesia. The study evaluated CATUVAB®, a device for intraoperative blood salvage in cancer surgeries. The primary endpoint of depleting EpCAM-positive cancer cells was met with high significance (p<0.0001). Safety endpoints showed no serious adverse events attributable to CATUVAB®.

The study, involving over 135 patients, demonstrated the device's efficacy and safety across various tumor types. CATUVAB® efficiently removes tumor cells, reducing metastatic potential in salvaged blood. This technology is poised to redefine intraoperative blood salvage protocols in oncology.

With CE certification underway, Lindis Blood Care anticipates a timely launch, reinforcing their Antibody-Based Cell Removal Technology's validity. Further development aims to enhance transfusion practices for immunosuppressed patients.